Based in Irvine, Calif., NeoMatrix develops innovative devices that allow women and their doctors to promote optimal breast health. The company's premier product, the HALO™ Breast Pap Test, is the only fully automated, noninvasive breast disease screening device designed for use in the Primary Care setting as part of an annual well-woman visit.

The HALO™ Breast Pap Test gives doctors and patients a new method to monitor breast cancer risk, quickly and easily. The fact is, all women are at risk for developing breast cancer. In the US we spend $3 billion annually on breast cancer screening, yet more than 70% of lumps are discovered during self-exams. Unfortunately, by the time a woman can actually feel the lump, the disease is no longer in its earliest, most treatable stage.

Thanks largely to the Pap test, deaths from cervical cancer have dropped more than 70% over the past fifty years. But only modest progress has been made in reducing deaths from breast cancer.

Like the cervical Pap test, the HALO system can detect abnormal cells years before a larger, potentially cancerous lesion might develop. This simple, noninvasive 5-minute test is the key to better outcomes through early detection.